Sponsors

MHRA to tackle evidence gaps on women’s health

Women are set to benefit from better evidence on medicines and medical devices, including how their risks and benefits may differ for women, under a new programme launched today by the Medicines and Healthcare products Regulatory Agency (MHRA).

Despite making up 51% of the population, women continue to face gaps in research and treatment across a range of health conditions. They have historically been underrepresented in clinical research, limiting the evidence available on medicines and medical devices during pregnancy and across reproductive health. Unmet needs also remain for conditions specific to women, as well as those that present differently or disproportionately in women.  

An MHRA analysis of all 4,616 UK clinical trial applications submitted between 2019 and 2023 highlighted continuing gaps in representation. Pregnant women were represented in just 1.1% of trials, while breastfeeding women were represented in 0.6%.  

The MHRA Women’s Health Programme 2026-2030, which launched on 16 November, aims to address these challenges and explore how better data and scientific advancements can more accurately reflect women’s needs.  

Lawrence Tallon, MHRA Chief Executive, said: “Closing the gaps in our understanding of how the risks and benefits of medicines and medical devices differ for women is both a challenge and a huge opportunity. Better evidence can help us understand where important differences exist, support researchers and innovators and create opportunities for healthcare that is better tailored to women’s needs.”  

Medicines and medical devices are complex, and factors such as biology, age, pregnancy and other health conditions can affect how people respond to them. The programme will bring together patients, researchers, healthcare professionals, and industry to strengthen the evidence available, while maintaining our robust standards of safety, quality and effectiveness.    

Women’s health is also a major area for innovation. The UK’s rapidly growing FemTech sector already has an annual turnover of nearly £300 million, with technologies being developed across areas from reproductive health to long-term conditions and healthy ageing.  

By working with researchers and innovators early and building better evidence about how the benefits and risks of medicines may differ for women, the MHRA wants to foster an environment where promising new products can be developed and reach patients earlier.  

The programme has been shaped by patients, including through the MHRA’s Patient and Public Community and a focus group delivered by the Patients Association. It is the first part of a wider MHRA initiative to address health inequalities as outlined in the recently launched 2030 Strategy.  

The Women’s Health Programme is the MHRA’s regulatory contribution to the wider government ambition to improve women’s health through the renewed Women’s Health Strategy for England and corresponding work in Scotland, Wales and Northern Ireland.  

The MHRA will host a webinar on Wednesday 9 December, from 11am to 12pm, introducing its Women’s Health Programme and outlining plans to strengthen evidence, support innovation in women’s health technologies and improve health outcomes for women. Register your interest via Eventbrite.

 

Latest Issues

POCT Innovators: Power to Disrupt - Clinical Diagnostics Now

Leonardo Royal Hotel, Oxford
16 November, 2025

DIA-MHRA Global Summit

Senate House, Malet Street, London, WC1E 7HU
16-17 November, 2026

UK NEQAS for Microbiology & Parasitology Annual Scientific Meeting 2026

The Royal National Hotel, 38 – 51 Bedford Way, London, WC1H 0DG
27 November, 2026

UK NEQAS webinar: Epigenetics

Online
1 December, 2026

UK NEQAS webinar: Fresh Muscle Biopsies

Online
8 December, 2026